Ex9 39

The following compounds were purchased from Bachem: SSTR2 antagonist (PRL-2915, catalog H-6056), Ex9–39 (catalog H-8740), GLP-1 (catalog H-6795), and Bombesin (catalog H-2155). Dimethyl sulfoxide (DMSO, CAS no. 67-68-5), 2-hydroxypropyl β-cyclodextrin (HPCD, catalog H107), and arginine (catalog A5131) were purchased from Sigma-Aldrich. The SSTR5 antagonist (compound B, 6-[[1-[(4-Chloro-3,5-diethoxyphenyl)methyl]-4-piperidinyl]amino]-3-pyridinecarboxylic acid; hydrochloride) was a gift from F. Hoffmann-La Roche Ltd. (22 (link)). The DPP-4i valine pyrrolidide was a gift from Novo Nordisk A/S.

For GLP-1R agonism, the SPF mice, and the ABX mice received an intraperitoneal injection of 4.2 μg/kg exenatide (Ex-4; Bachem)^{107 (link)} dissolved in 0.9% saline 30 minutes before behavior test. For GLP-1R antagonism, the ABX mice, the SPF mice, and the ABX-SDV mice were intraperitoneally injected with the 500 μg/kg exendin (9-39) (Ex(9-39); Bachem)^{108 (link)} dissolved in 0.9% saline 30 min before behavior test.
For CCK-induced food intake suppression, the SPF mice were intraperitoneally delivered with 8 μg/kg CCK-8 (Sigma-Aldrich) dissolved in 0.9% saline 30 min before behavior test.
For oxytocin receptor antagonism, 300 µg/kg L-371,257 (Tocris Bioscience) was administrated to mice intranasally. The L-371,257 powder was dissolved in 10% dimethyl sulfoxide (DMSO) in phosphate buffered saline (PBS). The solution was administered two microliters into each nostril 20 min before the behavior test.